相关实验视频

Updated: Feb 27, 2026

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Functionalized Spirocyclic Heterocycle Synthesis and Cytotoxicity Assay

Published on: February 9, 2021

设计,合成,抗癌评估和EGFR向分子对接的新型4- ((基基) -3-尼托皮里丁衍生物的设计,合成,抗癌评估和EGFR向分子对接的新型4- ((基基) -3-尼托皮里丁衍生物

Mahadevi Vitthal Kendre¹, Sachin S Bhusari¹, Pravin S Wakte¹

¹Department of Chemical Technology, Dr. Babasaheb Ambedkar Marathwada University, Chhatrapati Sambhajinagar, Maharashtra, India.

Chemistry & biodiversity

|February 25, 2026

概括

新的皮里丁衍生物对乳腺癌,肺癌和肝癌细胞系表现出强大的抗癌活性. 化合物MVK8-11显示强烈的结合EGFR,表明作为向癌症治疗的潜力.

科学领域:

药用化学医学化学
有机合成有机合成
药理学药理学是指药理学的学科.

背景情况:

开发新的抗癌药物对于有效的癌症治疗至关重要.
皮里丁衍生物已经被证明是有前途的细胞毒剂.
针对特定的细胞通路,如EGFR,是癌症治疗的关键策略.

研究的目的:

为了合成和表征新的4-基基) - - - - - - - - - - - - - - - - - - - - - - - - 尼特罗皮里丁衍生物.
评估这些衍生物在体外抗癌潜力,对抗人类癌症细胞系.
通过分子对接,研究有前途的化合物与EGFR变异的结合相互作用.

主要方法:

通过使用乙酸作为催化剂的凝结反应合成14种氨酸衍生物.
在体外细胞毒性测定对MCF7,A549和HepG2癌细胞系.
对野生型和突变EGFR结构进行分子对接研究 (PDBID: 5D41, 6LUD, 4I23).
使用Lipinski和Jorgensen规则进行ADME (吸收,分布,新陈代谢和排泄) 预测.

主要成果:

几种合成衍生品表现出显著的细胞毒性活性.
化合物MVK8-9对A549细胞 (IC50 = 2.5μM) 显示出高强度.
化合物MVK8-10对MCF7细胞 (IC50=4.78μM),MVK8-3对HepG2细胞 (IC50=3.712μM) 的作用最强.
化合物MVK8-11对EGFR变体表现出强烈的结合亲和力 (高达-7.401 kcal/mol).
大多数化合物表现出有利的药理动力学特性,遵守利宾斯基和约根森的规则,除了MVK8-12.

结论:

合成的4-基基) - 3 - 尼特罗皮里丁衍生物具有显著的抗癌潜力.
化合物MVK8-9,MVK8-10和MVK8-3是针对特定癌症细胞系的强有力的细胞毒剂.
作为一种向EGFR抑制剂,MVK8-11显示出有前途的作用,为癌症治疗开发提供了进一步的研究.
大多数衍生品表现出类似药物的特性,表明口服的可能性.

关键词:

A549和HepG2的使用情况.作为EGFR抑制剂的使用.MCF7 MCF7 MCF7 MCF7 MCF7 MCF7 MCF7 MCF7 MCF7 这里是船只基地.分子对接的分子对接.

更多相关视频

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Amide Coupling Reaction for the Synthesis of Bispyridine-based Ligands and Their Complexation to Platinum as Dinuclear Anticancer Agents

Published on: May 28, 2014

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

相关概念视频

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...